According to Zacks, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. “
Separately, Jefferies Group restated a buy rating and set a $4.50 price target (up previously from $4.00) on shares of Organovo Holdings in a report on Thursday, July 21st.
Shares of Organovo Holdings (NASDAQ:ONVO) opened at 3.93 on Thursday. The stock has a 50 day moving average of $3.92 and a 200-day moving average of $3.42. Organovo Holdings has a 52 week low of $1.60 and a 52 week high of $4.99.
Organovo Holdings (NASDAQ:ONVO) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Organovo Holdings had a negative net margin of 1,878.68% and a negative return on equity of 59.27%. Equities research analysts forecast that Organovo Holdings will post ($0.42) earnings per share for the current year.
In related news, EVP Eric David sold 20,000 shares of the firm’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of $4.55, for a total value of $91,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Advisors LLC raised its position in Organovo Holdings by 20.3% in the second quarter. BlackRock Advisors LLC now owns 39,509 shares of the company’s stock worth $147,000 after buying an additional 6,670 shares during the last quarter. A.R.T. Advisors LLC purchased a new position in Organovo Holdings during the second quarter worth about $231,000. Cowen Group Inc. raised its position in Organovo Holdings by 8.6% in the second quarter. Cowen Group Inc. now owns 63,000 shares of the company’s stock worth $234,000 after buying an additional 5,000 shares during the last quarter. Alliancebernstein L.P. raised its position in Organovo Holdings by 37.2% in the second quarter. Alliancebernstein L.P. now owns 73,050 shares of the company’s stock worth $272,000 after buying an additional 19,800 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Organovo Holdings by 19.5% in the second quarter. Rhumbline Advisers now owns 99,758 shares of the company’s stock worth $371,000 after buying an additional 16,245 shares during the last quarter. Institutional investors and hedge funds own 19.11% of the company’s stock.
Organovo Holdings Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.